MX2012002369A - Formas de anhidrato de un derivado de piridina. - Google Patents

Formas de anhidrato de un derivado de piridina.

Info

Publication number
MX2012002369A
MX2012002369A MX2012002369A MX2012002369A MX2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A MX 2012002369 A MX2012002369 A MX 2012002369A
Authority
MX
Mexico
Prior art keywords
pyridine derivative
anhydrate forms
anhydrate
forms
therapy
Prior art date
Application number
MX2012002369A
Other languages
English (en)
Inventor
Andrew Simon Craig
Salima Zarah Ismail
Ronnie Maxwell Lawrence
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2012002369A publication Critical patent/MX2012002369A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se relaciona al compuesto de fórmula (I) (ver fórmula (I)) en una forma cristalina del anhidrato, formulaciones farmacéuticas que los contienen, su uso en la terapia y procedimientos para preparar los mismos.
MX2012002369A 2009-08-27 2010-08-25 Formas de anhidrato de un derivado de piridina. MX2012002369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
MX2012002369A true MX2012002369A (es) 2012-03-29

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002369A MX2012002369A (es) 2009-08-27 2010-08-25 Formas de anhidrato de un derivado de piridina.

Country Status (18)

Country Link
US (1) US8796269B2 (es)
EP (1) EP2470545B1 (es)
JP (3) JP2013503134A (es)
KR (1) KR20120056258A (es)
CN (1) CN102639536B (es)
AU (1) AU2010288502B2 (es)
BR (1) BR112012003435A2 (es)
CA (1) CA2772168C (es)
DK (1) DK2470545T3 (es)
EA (1) EA021411B1 (es)
ES (1) ES2440938T3 (es)
IL (1) IL217922A (es)
IN (1) IN2012DN01292A (es)
MX (1) MX2012002369A (es)
PL (1) PL2470545T3 (es)
SG (1) SG178231A1 (es)
WO (1) WO2011023733A1 (es)
ZA (1) ZA201200812B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2470545T3 (da) * 2009-08-27 2014-01-13 Nerre Therapeutics Ltd Anhydrate former af et pyridinderivat
ES2879375T3 (es) * 2014-06-25 2021-11-22 Univ Emory Procedimientos de manejo del miedo condicionado con antagonistas del receptor de neuroquinina
RU2743206C2 (ru) * 2015-05-18 2021-02-16 Кэнди Терапьютикс Лимитед Двойные антагонисты рецептора нейрокинин-1/нейрокинин-3 для лечения заболеваний, зависимых от половых гормонов
CA3044773A1 (en) * 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 activators
AU2019233606A1 (en) 2018-03-14 2020-09-17 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
WO2021094247A1 (en) 2019-11-15 2021-05-20 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
CN100562320C (zh) * 2003-01-31 2009-11-25 弗·哈夫曼-拉罗切有限公司 2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
CA2621564C (en) * 2005-09-09 2014-06-03 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
KR20100101051A (ko) * 2007-12-11 2010-09-16 씨아이피엘에이 엘티디. 조피클론 결정성 다형체, 이들의 제조 공정 및 이들의 약제 조성물
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
DK2470545T3 (da) * 2009-08-27 2014-01-13 Nerre Therapeutics Ltd Anhydrate former af et pyridinderivat
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
PL2470545T3 (pl) 2014-03-31
US20120157450A1 (en) 2012-06-21
SG178231A1 (en) 2012-03-29
IL217922A (en) 2016-06-30
ZA201200812B (en) 2013-03-27
WO2011023733A1 (en) 2011-03-03
ES2440938T3 (es) 2014-01-31
CA2772168A1 (en) 2011-03-03
EA021411B1 (ru) 2015-06-30
CA2772168C (en) 2019-01-08
IL217922A0 (en) 2012-03-29
CN102639536A (zh) 2012-08-15
US8796269B2 (en) 2014-08-05
BR112012003435A2 (pt) 2016-02-23
EA201270302A1 (ru) 2012-07-30
KR20120056258A (ko) 2012-06-01
CN102639536B (zh) 2015-03-18
JP6404186B2 (ja) 2018-10-10
JP2013503134A (ja) 2013-01-31
EP2470545A1 (en) 2012-07-04
JP2017193564A (ja) 2017-10-26
AU2010288502B2 (en) 2013-12-12
EP2470545B1 (en) 2013-10-09
AU2010288502A1 (en) 2012-02-23
IN2012DN01292A (es) 2015-06-05
DK2470545T3 (da) 2014-01-13
JP2016000739A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
NZ608116A (en) Triazine-oxadiazoles
MX2012000414A (es) Derivados piridin-4-ilo.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX342212B (es) Inhibidores de neprilisina.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MX2012013274A (es) Novedosos derivados de la pirimidina.
IN2014CN04530A (es)
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
MX2013010898A (es) Novedoso derivados de la pirimidina.
IN2012DN03182A (es)
PH12015500376A1 (en) Novel bicyclic pyridinones
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
IN2012DN02139A (es)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
TW200833335A (en) New pyridine analogues
TW200833333A (en) New pyridine analogues
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
MY150428A (en) Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NERRE THERAPEUTICS LIMITED

FG Grant or registration